EP Patent

EP3045176B1 — Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydroisoindol-2-yl)-piperidine-2,6-dione

Assigned to Celgene Corp · Expires 2018-11-07 · 8y expired

What this patent protects

Patent listed against Revlimid.

Drugs covered by this patent

Patent Metadata

Patent number
EP3045176B1
Jurisdiction
EP
Classification
—
Expires
2018-11-07
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.